** Eli Lilly LLY.N shares dip 1.4% premarket to $872.32 after HSBC double downgrades rating to "reduce" from "buy"
** Brokerage also cuts TP to $700 from $1150, saying there is "too much optimism in the price"
** HSBC says obesity drug sector is sensitive to macro environment and sector's growth risk due to higher unemployment numbers is unknown
** "We prefer Novo (Nordisk) over Lilly at the current share price", HSBC adds
** Brokerage also downgrades Roche ROG.S, Biogen BIIB.O to "hold" from "buy," citing forex and China diagnostics risks for Roche and slow Alzheimer's adoption for Biogen
** 23 out of 29 analysts rate stock "buy" or higher, 5 "hold" and 1 "sell", median PT is $1000, as per LSEG data
** YTD, Of last close, LLY up 14.6%, ROG up 3.6% and BIO down 22.3%
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。